Document Detail


Prognostic factors for newly diagnosed prostate cancer and their role in treatment selection.
MedLine Citation:
PMID:  23763882     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Adenocarcinoma of the prostate is extremely heterogeneous, ranging from an indolent chronic illness to an aggressive rapidly fatal systemic malignancy. The classic prognostic factors of tumor stage, prostate specific antigen level, and Gleason score have been used for over a decade to categorize patients at the time of diagnosis into broad risk groups that help to determine appropriate management. Although the grouping of patients into favorable, intermediate, and high-risk categories has become standard, and the categories continue to define distinct prognostic subgroups, considerable heterogeneity exists within each risk group. As a range of management options are available, additional prognostic factors can be considered when determining the treatment approach for an individual patient. We review these additional prognostic variables under the headings of patient-related, tumor-related, and treatment-related. The influence of each of these factors may vary depending on treatment factors such as dose, the radiation modality, or the use of concomitant androgen ablation.
Authors:
Juanita Crook; Ana Fernandez Ots
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Seminars in radiation oncology     Volume:  23     ISSN:  1532-9461     ISO Abbreviation:  Semin Radiat Oncol     Publication Date:  2013 Jul 
Date Detail:
Created Date:  2013-06-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9202882     Medline TA:  Semin Radiat Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  165-72     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 Elsevier Inc. All rights reserved.
Affiliation:
Department of Radiation Oncology, British Columbia Cancer Agency, Center for the Southern Interior, Kelowna, British Columbia, Canada. Electronic address: jcrook@bccancer.bc.ca.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Multidisciplinary care and management selection in prostate cancer.
Next Document:  How can I help myself? A critical review of modifiable behaviors, medications, and complementary alt...